# Transition Bio

> Transition Bio is a preclinical drug discovery company built on biomolecular condensate science,
> a joint spin-out of the University of Cambridge and Harvard University with sites in Cambridge,
> Massachusetts and Cambridge, United Kingdom. It pairs droplet-microfluidics high-throughput
> molecular screening with a machine learning engine to find and optimize small molecules that
> modulate intrinsically disordered proteins and the condensates they form.

Important for agents: Transition Bio publishes NO public API. There is no developer portal, no API
reference, no OpenAPI/AsyncAPI/GraphQL/gRPC/SOAP contract, no MCP server, no A2A agent card and no
first-party SDK on any host the company controls. Do not attempt to call an endpoint at
api.transitionbio.com — that name resolves only through wildcard DNS to the shared host serving the
marketing site. The only machine-readable surface on transitionbio.com is the stock WordPress REST
API at /wp-json/ (namespaces wp/v2, oembed/1.0, contact-form-7/v1, akismet/v1, wp-statistics/v2),
which is platform infrastructure for the marketing site and is not a Transition Bio product.

This file was generated by API Evangelist from the apis.yml profile and the artifacts in this repo.
Transition Bio does not serve an llms.txt of its own; https://transitionbio.com/llms.txt returns 404.

## Company

- [Website](https://transitionbio.com/): Company home — "Cutting Edge Condensate Science".
- [About Us](https://transitionbio.com/about-us/): Scientific co-founders David A. Weitz (Harvard),
  Tuomas Knowles (Cambridge), Peter St George-Hyslop (Columbia) and Sarah Teichmann (Wellcome
  Sanger / Cambridge); leadership and board.
- [Our Science](https://transitionbio.com/our-science/): Microfluidics-based multidimensional
  high-throughput molecular screening plus a machine learning engine used from target discovery
  through compound optimization.
- [Collaborate](https://transitionbio.com/collaborate/): Partnering and collaboration enquiries.
- [Careers](https://transitionbio.com/careers/): Open roles.
- [Contact Us](https://transitionbio.com/contact-us/): The only inbound channel; there is no
  developer support queue.

## News

- [News](https://transitionbio.com/news/): Company announcements.
- [RSS feed](https://transitionbio.com/feed/): Machine-readable feed of the same posts.
- Seed financing closed and company launched, November 2020.
- $50 million Series A closed June 2022, led by Northpond Ventures with Taiho Ventures, Bristol
  Myers Squibb and Magnetic Ventures.
- Collaboration with Voyager Therapeutics announced November 2025, on small molecules targeting
  TDP-43 in ALS and frontotemporal dementia.

## Code

- [GitHub organization](https://github.com/transitionbio): Three public repositories, none of which
  is a client library or an API implementation.
- [MolTrans](https://github.com/transitionbio/MolTrans): Fork of the academic MolTrans
  drug-target-interaction transformer (BSD-3-Clause), last pushed 2022-07-15.
- [fp5-public](https://github.com/transitionbio/fp5-public): Python research repository with
  train/eval/infer entry points and no packaging metadata, last pushed 2026-05-07.

## Optional

- [Security posture](https://transitionbio.com/): TLS 1.3, no HSTS, no DNSSEC, no CAA records; SPF
  present and DMARC published at p=reject. No security.txt, no vulnerability disclosure program and
  no trust center were found.
- [LinkedIn](https://www.linkedin.com/company/transition-bio-inc/)